GlassScriptPhysician profile
Christen Carter
NPI 1609549724
$776.04
in general payments reported to CMS, 2019-2025
12 companies · $82.83 in 2025
The $82.83 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $117 · 2023: $172 · 2024: $283 · 2025: $82.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.77 | 2021-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $124.80 | 2023-2024 | Tarpeyo |
| Amgen INC. | $93.36 | 2024 | Tavneos, Krystexxa, Parsabiv |
| Fresenius USA Marketing, INC. | $74.22 | 2024-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $66.00 | 2023 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.82 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $24.95 | 2024 | Ultomiris |
| Travere Therapeutics, INC. | $22.55 | 2024 | |
| Novo Nordisk INC | $21.61 | 2024 | Ozempic, Rybelsus |
| Ardelyx, INC. | $21.07 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $19.90 | 2024 | Benlysta |
| Intuitive Surgical, INC. | $16.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christen Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.